Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04789577 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine GSK3206641A Administered in Adults 18 to 64 Years of Age and 65 Years of Age and Older
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 833
- Enrollment target
NCT04789577 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 833 participants.
The verdict
NCT04789577, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 833 participants
- Enrollment target
Study Summary
Study to evaluate the safety and immunogenicity of H7N9 antigen in combination with full or half doses of AS03 adjuvant system in healthy adults.
Interventions
- BIOLOGICAL FLU-Q-PAN H7N9 Formulation 1
- BIOLOGICAL FLU-Q-PAN H7N9 Formulation 2
- BIOLOGICAL FLU-Q-PAN H7N9 Formulation 3
- BIOLOGICAL AS03B
- BIOLOGICAL AS03A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 833 participants |
| Start Date | 2021-03-16 |
| Est. Completion | 2022-09-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04789577
The ClinicalTrials.gov registry entry for NCT04789577 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 833 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which FLU-Q-PAN H7N9 Formulation 1 is the first listed.
NCT04789577 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04789577 about?
NCT04789577 is a clinical study titled "A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine GSK3206641A Administered in Adults 18 to 64 Years of Age and 65 Years of Age and Older". Study to evaluate the safety and immunogenicity of H7N9 antigen in combination with full or half doses of AS03 adjuvant system in healthy adults.
What is the current status of trial NCT04789577?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 833 participants. The study started on 2021-03-16. Estimated completion is 2022-09-12.
What interventions are being tested in trial NCT04789577?
The interventions under investigation include: FLU-Q-PAN H7N9 Formulation 1 (BIOLOGICAL), FLU-Q-PAN H7N9 Formulation 2 (BIOLOGICAL), FLU-Q-PAN H7N9 Formulation 3 (BIOLOGICAL), AS03B (BIOLOGICAL), AS03A (BIOLOGICAL).
Who is sponsoring clinical trial NCT04789577?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.